Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx stock price

If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart. 

The stock gapped up nearly 28% on July 17, after announcing better-than-expected results from a clinical trial of its treatment for patients suffering from a progressive condition that affects muscle control. 

After that gap higher, the stock pulled back into a shallow cup pattern, and it’s now adding a handle to that. So far, the base has corrected only 7%, a very shallow pullback. The fact that it’s pulled back such a small amount, and is far from closing the gap, indicates that investors have the conviction to continue holding. 

The stock’s current buy point is above $532.60, which is the high point of the handle. 

Positive Clinical Trial Results

Driving the gap-up: Over the course of a 48-week study, patients who received the company’s Vyvgart Hytrulo saw a 61% decline in the risk of relapse versus those receiving a placebo.

Netherlands-based Argenx is a biopharmaceutical company that develops antibody-based therapies to treat severe autoimmune diseases and other conditions.

Despite never having posted a profit, Argenx has a market capitalization of $29.30 billion. That’s unusual; most unprofitable biotechs are much smaller. 

So what’s behind that substantial market capitalization? 

The company has built up a robust drug pipeline with potential treatments for severe autoimmune diseases, as well as thyroid and skin conditions. In the biotech industry, investors often prioritize the potential of drug candidates, even if the company hasn't generated profits yet.

Biotech Sector Commands High Valuations

In general, the biotechnology sector tends to command high valuations because investors are eager to hop on board and invest in innovative treatments. Investors know biotech can be incredibly risky, but the rewards can also be great. 

For example, Argenx is viewed as a potential acquisition target by a larger pharmaceutical firm. 

For example, its portfolio of autoimmune drugs could be an attractive addition for a large pharma company such as AbbVie Inc. (NYSE: ABBV), which is facing patent expirations in a few years. Analysts say many of AbbVie’s drugs will reach peak revenue potential around the time that AbbVie’s revenue stream is under pressure. 

In addition, analysts believe Vyvgart Hytrulo has the potential to get regulators’ OK to treat a number of other conditions, greatly increasing the likelihood of cash flow gains. Vygart is currently the company’s only product that’s generating revenue. 

Healthcare stocks from the pharmaceutical and biotech industries that focus on antibody therapies include AbbVie, as well as Bristol-Myers Squibb Co. (NYSE: BMY)Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), AstraZeneca PLC  (NASDAQ: AZN), Amgen Inc. (NASDAQ: AMGN), AbCellera Biologics Inc. (NASDAQ: ABCL), Incyte Corp. (NASDAQ: INCY),   Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)AnaptysBio, Inc. (NASDAQ: ANAB) and Viela Bio, Inc. (NASDAQ: VIE).

Revenue From Vygart, Collaborations

In the second quarter, Argenx reported $269 million in global revenue from Vyvgart. The company also generates revenue from collaborations, such as a partnership with Denmark’s Genmab to jointly discover, develop and commercialize therapeutic antibodies with applications in immunology and oncology. 

In the past four quarters, Argenx revenue grew at triple or quadruple-digit rates, versus the year-earlier quarter. Those gains are due to a fast ramp-up of Vygart sales. 

Wall Street still doesn’t see any profit in the next couple of years, which is common for biotechs still ramping up product sales.

On Track To Become Powerhouse

However, over the medium and long term, analysts are fans of this stock, likely due to a combination of increasing sales and the company’s potential as an acquisition target.

In a recent interview with pharmaceutical trade publication Fierce Pharma, Argenx CEO Tim Van Hauwermeiren said the company is on its way to becoming an immunology “powerhouse” within just a few years.

MarketBeat’s Argenx analyst ratings show a consensus view of “moderate buy,” with a price target of $533.95, an upside of 5.56%. 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.